StreetInsider.com News Articles

Form 4 MapLight Therapeutics, For: Oct 15 Filed by: Kroeger Christopher A.

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198556.html

Form 4 MapLight Therapeutics, For: Oct 15 Filed by: Lillie James Woodruff

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198562.html

Form 4 MapLight Therapeutics, For: Oct 15 Filed by: GILLIS JONATHAN

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198564.html

Form 4 MapLight Therapeutics, For: Oct 15 Filed by: Hanson Kristopher

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198565.html

Form 4 MapLight Therapeutics, For: Oct 15 Filed by: Foff Erin Pennock

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198571.html

Form 4 MapLight Therapeutics, For: Oct 15 Filed by: Kreitzer Anatol

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198573.html

Form 144 MapLight Therapeutics, Filed by: Hanson Kristopher

Thu, 15 Oct 2026 18:36:00 -0400

si-local-file:///var/storage/secattach/20261015/27194414.html

Form 144 MapLight Therapeutics, Filed by: GILLIS JONATHAN

Thu, 15 Oct 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20261015/27194333.html

Form 144 MapLight Therapeutics, Filed by: Foff Erin Pennock

Thu, 15 Oct 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20261015/27194293.html

Form 144 MapLight Therapeutics, Filed by: Kroeger Christopher A.

Thu, 15 Oct 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20261015/27194250.html

Form 144 MapLight Therapeutics, Filed by: Lillie James Woodruff

Thu, 15 Oct 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20261015/27194160.html

Form 144 MapLight Therapeutics, Filed by: Malenka Robert C.

Thu, 15 Oct 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20261015/27193881.html

Form 144 MapLight Therapeutics, Filed by: Kreitzer Anatol

Thu, 15 Oct 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20261015/27193458.html

MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

Tue, 06 Oct 2026 07:00:00 -0400

Award honors foundational discoveries in optogenetics and circuit mapping

These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery

SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics (Nasdaq: MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine. Dr. Deisseroth shares the honor with Peter Hegemann, Ph.D., of Humboldt University of Berlin, and Georg Nagel, Ph.D., of the University of Würzburg, for their discoveries concerning

MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

Tue, 06 Oct 2026 07:00:00 -0400

Award honors foundational discoveries in optogenetics and circuit mapping

These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery

Guggenheim Starts MapLight Therapeutics (MPLT) at Neutral

Mon, 05 Oct 2026 16:06:50 -0400

Guggenheim analyst Delma Caiati initiates coverage on MapLight Therapeutics (NASDAQ: MPLT) with a Neutral rating.

For an analyst ratings summary and ratings history on MapLight Therapeutics click here. For more ratings news on MapLight Therapeutics click here.

Shares of MapLight Therapeutics closed at $9.82 yesterday.

Form EFFECT MapLight Therapeutics,

Thu, 24 Sep 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260924/27098427.html

Form 424B3 MapLight Therapeutics,

Wed, 23 Sep 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260923/27096966.html

Form S-1/A MapLight Therapeutics,

Fri, 18 Sep 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260918/27080722.html

Form 4 MapLight Therapeutics, For: Sep 16 Filed by: Hanson Kristopher

Fri, 18 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260918/27080704.html

Form 144 MapLight Therapeutics, Filed by: Hanson Kristopher

Wed, 16 Sep 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260916/27070530.html

MapLight Therapeutics to Participate in Upcoming Investor Conference

Wed, 09 Sep 2026 07:00:00 -0400

SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:

Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY)
Date: Monday, September 14^th
Format: Presenting and hosting 1x1 meetings

Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.

About MapLight Therapeutics

MapLight Therapeutics

MapLight Therapeutics to Participate in Upcoming Investor Conference

Wed, 09 Sep 2026 07:00:00 -0400

Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY)
Date: Monday, September 14^th
Format: Presenting and hosting 1x1 meetings

About MapLight Therapeutics

MapLight Therapeutics

MapLight Therapeutics (MPLT) PT Lowered to $43 at Needham

Mon, 31 Aug 2026 07:19:45 -0400

(Updated - August 31, 2026 7:19 AM EDT)

Needham analyst Ami Fadia lowered the price target on MapLight Therapeutics (NASDAQ: MPLT) to $43.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: "MPLT reported its 2Q26 earnings recently as well as announced a PIPE financing of $150M. We update our model for both these events which reduced our PT to $43 based on dilution of shares and anticipated raise/dilution for the following year. We continue to see MPLT undervalued at current levels with the differentiation for ML-007C-MA on safety and dosing convenience underappreciated for both schizophrenia and ADP. For the remainder

MapLight Therapeutics (MPLT) PT Lowered to $43 at Needham

Mon, 31 Aug 2026 07:19:45 -0400

(Updated - August 31, 2026 7:19 AM EDT)

Needham analyst Ami Fadia lowered the price target on MapLight Therapeutics (NASDAQ: MPLT) to $43.00 (from $45.00) while maintaining a Buy rating.